Skip to main content

13 August 2021

Viral vector engineering to improve clinical performance & accelerate timelines for novel therapies

OXGENE

Editorial/Manufacturing Chemist/13 August 2021

View More

Abstract

Advanced therapy manufacturers have taken the head start that Nature’s given them and used developments in genetic engineering, computational biology and bioinformatics to perfect the viral particle as a vector for therapeutic DNA and hasten the clinical success of groundbreaking new treatments.

Here, we look into three aspects of viral biology that make them efficient delivery vehicles for gene therapies — and some of the ways that biologists have taken advantage of these properties to improve clinical performance.

View the paper in full here.
×